Cargando…

Facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective

BACKGROUND: Accrual to Cancer Control and Supportive Care (CCL) studies can be challenging. Our objective was to identify facilitators and perceived barriers to successful Children’s Oncology Group (COG) CCL accrual from the clinical research associate (CRA) perspective. METHODS: A survey was develo...

Descripción completa

Detalles Bibliográficos
Autores principales: VanHoff, David, Hesser, Tanya, Kelly, Katherine Patterson, Freyer, David, Stork, Susan, Sung, Lillian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897981/
https://www.ncbi.nlm.nih.gov/pubmed/24380578
http://dx.doi.org/10.1186/1471-2288-13-154
_version_ 1782300335686025216
author VanHoff, David
Hesser, Tanya
Kelly, Katherine Patterson
Freyer, David
Stork, Susan
Sung, Lillian
author_facet VanHoff, David
Hesser, Tanya
Kelly, Katherine Patterson
Freyer, David
Stork, Susan
Sung, Lillian
author_sort VanHoff, David
collection PubMed
description BACKGROUND: Accrual to Cancer Control and Supportive Care (CCL) studies can be challenging. Our objective was to identify facilitators and perceived barriers to successful Children’s Oncology Group (COG) CCL accrual from the clinical research associate (CRA) perspective. METHODS: A survey was developed that focused on the following features from the institutional perspective: (1) Components of successful accrual; (2) Barriers to accrual; (3) Institutional changes that could enhance accrual; and (4) How COG could facilitate accrual. The survey was distributed to the lead CRA at each COG site with at least 2 CCL accruals within the previous year. The written responses were classified into themes and sub-themes. RESULTS: 57 sites in the United States (n = 52) and Canada (n = 5) were contacted; 34 (60%) responded. The four major themes were: (1) Staff presence and dynamics; (2) Logistics including adequate numbers of eligible patients; (3) Interests and priorities; and (4) Resources. Suggestions for improvement began at the study design/conception stage, and included ongoing training/support and increased reimbursement or credit for successful CCL enrollment. CONCLUSIONS: The comments resulted in suggestions to facilitate CCL trials in the future. Soliciting input from key team members in the clinical trials process is important to maximizing accrual rates.
format Online
Article
Text
id pubmed-3897981
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38979812014-01-23 Facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective VanHoff, David Hesser, Tanya Kelly, Katherine Patterson Freyer, David Stork, Susan Sung, Lillian BMC Med Res Methodol Research Article BACKGROUND: Accrual to Cancer Control and Supportive Care (CCL) studies can be challenging. Our objective was to identify facilitators and perceived barriers to successful Children’s Oncology Group (COG) CCL accrual from the clinical research associate (CRA) perspective. METHODS: A survey was developed that focused on the following features from the institutional perspective: (1) Components of successful accrual; (2) Barriers to accrual; (3) Institutional changes that could enhance accrual; and (4) How COG could facilitate accrual. The survey was distributed to the lead CRA at each COG site with at least 2 CCL accruals within the previous year. The written responses were classified into themes and sub-themes. RESULTS: 57 sites in the United States (n = 52) and Canada (n = 5) were contacted; 34 (60%) responded. The four major themes were: (1) Staff presence and dynamics; (2) Logistics including adequate numbers of eligible patients; (3) Interests and priorities; and (4) Resources. Suggestions for improvement began at the study design/conception stage, and included ongoing training/support and increased reimbursement or credit for successful CCL enrollment. CONCLUSIONS: The comments resulted in suggestions to facilitate CCL trials in the future. Soliciting input from key team members in the clinical trials process is important to maximizing accrual rates. BioMed Central 2013-12-31 /pmc/articles/PMC3897981/ /pubmed/24380578 http://dx.doi.org/10.1186/1471-2288-13-154 Text en Copyright © 2013 VanHoff et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
VanHoff, David
Hesser, Tanya
Kelly, Katherine Patterson
Freyer, David
Stork, Susan
Sung, Lillian
Facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective
title Facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective
title_full Facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective
title_fullStr Facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective
title_full_unstemmed Facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective
title_short Facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective
title_sort facilitating accrual to cancer control and supportive care trials: the clinical research associate perspective
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897981/
https://www.ncbi.nlm.nih.gov/pubmed/24380578
http://dx.doi.org/10.1186/1471-2288-13-154
work_keys_str_mv AT vanhoffdavid facilitatingaccrualtocancercontrolandsupportivecaretrialstheclinicalresearchassociateperspective
AT hessertanya facilitatingaccrualtocancercontrolandsupportivecaretrialstheclinicalresearchassociateperspective
AT kellykatherinepatterson facilitatingaccrualtocancercontrolandsupportivecaretrialstheclinicalresearchassociateperspective
AT freyerdavid facilitatingaccrualtocancercontrolandsupportivecaretrialstheclinicalresearchassociateperspective
AT storksusan facilitatingaccrualtocancercontrolandsupportivecaretrialstheclinicalresearchassociateperspective
AT sunglillian facilitatingaccrualtocancercontrolandsupportivecaretrialstheclinicalresearchassociateperspective